All In Biotech

NDA 207793 · Ipsen

Onivyde

Irinotecan Hydrochloride · Intravenous

Priority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Dec 23, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Oct 22, 2015

Approved uses

2

Original approval plus efficacy supplements

Registered trials

2,083

325 Phase 3, 315 recruiting

FAERS reports

9,837

9,369 serious, 1,809 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SEVERE NEUTROPENIA AND SEVERE DIARRHEA Neutropenia Severe and life-threatening neutropenia, including fatal neutropenic sepsis and fatal neutropenic fever, has occurred in patients receiving ONIVYDE in combination with oxaliplatin, fluorouracil and leucovorin and in combination with fluorouracil and leucovorin. Withhold ONIVYDE for absolute neutrophil count below 1500/mm 3 or neutropenic fever. Monitor blood cell counts periodically during treatment [see Dosage and Administration (2.2) and Warnings and Precautions (5.1) ]. Diarrhea Severe and life-threatening diarrhea has occurred in patients receiving ONIVYDE in combination with oxaliplatin, fluorouracil and leucovorin and in combination with fluorouracil and leucovorin. Do not administer ONIVYDE to patients with bowel obstruction. Withhold ONIVYDE for diarrhea of Grade 2-4 severity. Administer loperamide for late diarrhea of...

What it is approved for

From the label in effect Mar 3, 2025.

ONIVYDE is indicated, in combination with oxaliplatin, fluorouracil and leucovorin for the first-line treatment of adult patients with metastatic pancreatic adenocarcinoma. ONIVYDE is indicated, in combination with fluorouracil and leucovorin, for the treatment of adult patients with metastatic pancreatic adenocarcinoma after disease progression following gemcitabine-based therapy. Limitations of Use: ONIVYDE is not indicated as a single agent for the treatment of patients with metastatic pancreatic adenocarcinoma. [see Clinical Studies (14) ] . ONIVYDE is a topoisomerase inhibitor indicated: in combination with oxaliplatin, fluorouracil and leucovorin, for the first-line treatment of adult patients with metastatic pancreatic adenocarcinoma, ( 1 ) in combination with fluorouracil and leucovorin, for the treatment of adult patients with metastatic pancreatic adenocarcinoma after disease progression following gemcitabine-based therapy. ( 1 ) Limitation of Use: ONIVYDE is not indicated as a single agent for the treatment of patients with metastatic pancreatic adenocarcinoma. ( 1 )

Mechanism: Irinotecan liposome injection is a topoisomerase 1 inhibitor encapsulated in a lipid bilayer vesicle or liposome. Topoisomerase 1 relieves torsional strain in DNA by inducing single-strand breaks. Irinotecan and its active metabolite SN-38 bind reversibly to the topoisomerase 1-DNA complex and prevent re-ligation of the single-strand breaks, leading to exposure time-dependent double-strand DNA damage and cell death. In mice bearing human tumor xenografts, irinotecan liposome administered at irinotecan HCl-equivalent doses 5-fold lower than irinotecan HCl achieved similar intratumoral exposure...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 13, 2024 Supplement 16 · Efficacy OrphanLabelLetter
  • Oct 22, 2015 Original approval · Type 5 - New Formulation or New Manufacturer · priority review OrphanReviewLabelLetter
1 products under this application
  • ONIVYDE · IRINOTECAN HYDROCHLORIDE EQ 43MG BASE/10ML (EQ 4.3MG BASE/ML) · INJECTABLE, LIPOSOMAL, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Irinotecan" as an intervention, any sponsor and status, largest first.

All 2,083 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea1,225
  • off label use980
  • myelosuppression719
  • nausea645
  • vomiting569
  • malignant neoplasm progression548
  • febrile neutropenia538
  • death512
  • neutropenia468
  • neuropathy peripheral443
  • disease progression426
  • fatigue420

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200411
20059
20066
20072
2008143
200984
2010123
2011224
2012291
2013243
2014158
2015335
2016312
2017313
2018414
2019488
2020548
2021638
2022863
20231,022
20241,083
20251,475
20261,052

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Onivyde (Irinotecan Liposomal)

2024 spending

$2.2M

Beneficiaries

47

167 claims

Per beneficiary

$47,526

$275.43 per unit

View as table
YearSpending
2020$293,344
2021$442,132
2022$757,636
2023$1,358,977
2024$2,233,736

Part B: Onivyde (Irinotecan Liposomal) · HCPCS J9205

2024 spending

$87.9M

Beneficiaries

2,165

11,509 claims

Per beneficiary

$40,586

2024 ASP limit $63.40 per unit

View as table
YearSpending
2020$53,152,629
2021$56,731,827
2022$63,047,522
2023$74,036,599
2024$87,869,105

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,762 on PubMed

Sponsor: Ipsen

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.